RPL17 and breast cancer: Additionally, ANXA1 was significantly decreased in expression in breast cancer tissues compared to normal tissues and demonstrated increased expression in nonresponders to PD‐1/PD‐L1 therapies in TNBC patients, suggesting its potential involvement in immunotherapy resistance despite lacking a direct correlation with overall survival rates.